M. Gottardis

发表

Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.

V. Jordan, M. Gottardis, Jordan Vc, 1987, Cancer research.

Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.

S. Robinson, V. Jordan, P. Satyaswaroop, 1988, Cancer research.

Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration.

V. Jordan, M. Gottardis, 1988, Cancer research.

Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1).

S. Pang, G. Trainor, M. Poss, 2009, Bioorganic & medicinal chemistry letters.

Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)--Hit to Lead studies.

S. Pang, G. Trainor, M. Poss, 2009, Bioorganic & medicinal chemistry letters.

A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation

P. Sorensen, C. Chow, G. Morin, 2012, Oncogene.

The Prostate GREB 1 is aNovelAndrogen-RegulatedGene Required for ProstateCancerGrowth

K. Pienta, J. Scheys, Michael D. Johnson, 2006 .

GREB1 is a novel androgen‐regulated gene required for prostate cancer growth

Kenneth J Pienta, K. Pienta, J. Scheys, 2006, The Prostate.

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

H. Masoudi, R. Nicholson, S. Dunn, 2008, Cancer research.

Tamoxifen‐stimulated Growth of Human Endometrial Carcinoma

V. Jordan, P. Satyaswaroop, M. Gottardis, 1991, Annals of the New York Academy of Sciences.

Immune-deficient animals to study "hormone-dependent" breast and endometrial cancer.

A. Friedl, S. Robinson, V. Jordan, 1989, Journal of steroid biochemistry.

Assessing compound binding to the Eg5 motor domain using a thermal shift assay.

M. Doyle, V. Goldfarb, W. Metzler, 2009, Analytical biochemistry.

Drug safety is a barrier to the discovery and development of new androgen receptor antagonists

J. Arezzo, M. Salvati, A. Balog, 2011, The Prostate.

Effect of cadmium on estrogen receptor levels and estrogen-induced responses in human breast cancer cells.

D. Salomon, N. Kenney, V. Jordan, 1994, The Journal of biological chemistry.

Regulation of estrogen receptor expression

M. Gottardis, M. Martin, M. Saceda, 2004, Breast Cancer Research and Treatment.

High-frequency pulsation (HFP) in a patient with Guillain-Barré syndrome

M. Gottardis, M. Neumann, G. Putz, 2005, Intensive Care Medicine.

Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.

M. Gottardis, R. Attar, A. Greer, 2007, Bioorganic & medicinal chemistry letters.

Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel).

M. Gottardis, P. LaPointe, V. Vivat-Hannah, 2001, Cancer research.

Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.

Chiehying Y Chang, M. Gottardis, R. Attar, 2005, Journal of medicinal chemistry.

Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R).

D. Langley, J. Sack, Chiehying Y Chang, 2007, Bioorganic & medicinal chemistry letters.

2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924.

D. Langley, M. Gottardis, R. Attar, 2008, Bioorganic & medicinal chemistry letters.

Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.

G. Trainor, A. Mathur, D. Langley, 2009, Journal of medicinal chemistry.

Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.

G. Trainor, M. Gottardis, A. Greer, 2010, Bioorganic & medicinal chemistry letters.

Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.

S. Spergel, G. Trainor, L. Schweizer, 2015, ACS medicinal chemistry letters.

Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

F. Huang, P. Haluska, M. Gottardis, 2011, Cancer research.

Retinoid-induced suppression of squamous cell differentiation in human oral squamous cell carcinoma xenografts (line 1483) in athymic nude mice.

J. Hayes, M. Gottardis, D. Shalinsky, 1995, Cancer research.

Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists.

J. Chen, L. Schweizer, M. Salvati, 2010, Bioorganic & medicinal chemistry letters.

Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.

Michael A. Galella, A. Fura, S. Krystek, 2008, Bioorganic & medicinal chemistry letters.

Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.

J. Hunt, Donna D Wei, M. Salvati, 2005, Bioorganic & medicinal chemistry letters.

Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.

K. Kish, S. Krystek, Donna D Wei, 2005, Bioorganic & medicinal chemistry letters.

The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists.

J. Tokarski, A. Mathur, L. Leith, 2004, Bioorganic & medicinal chemistry letters.

Effects of progesterone administration on N-nitrosomethylurea-induced rat mammary carcinogenesis.

M. Gottardis, D. Rose, E. Ertürk, 1983, European journal of cancer & clinical oncology.

9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.

J. Tokarski, G. Trainor, J. Sack, 2015, Bioorganic & medicinal chemistry letters.

Endocrine abnormalities in severe traumatic brain injury —a cue to prognosis in severe craniocerebral trauma?

E. Rumpl, M. Gottardis, J. Hackl, 2005, Intensive Care Medicine.

Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice.

V. Jordan, P. Satyaswaroop, M. Gottardis, 1990, Cancer research.

Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens.

V. Jordan, M. Gottardis, Shun-yuan Jiang, 1989, Cancer research.

Enhanced growth of an estrogen receptor-negative endometrial adenocarcinoma by estradiol in athymic mice.

A. Friedl, J. Pink, V. Jordan, 1989, Cancer research.

Effects of AGM-1470 and pentosan polysulphate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells.

B. Trock, S. McLeskey, S. Kharbanda, 1996, British Journal of Cancer.

Estrogen receptor activation via activation function 2 predicts agonism of xenoestrogens in normal and neoplastic cells of the uterine myometrium.

R. Fuchs-Young, L. Hodges, C. Walker, 1999, Cancer research.

Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo.

C. Walker, J. Everitt, M. Gottardis, 1995, Endocrinology.

Estrogen/Antiestrogen Responsiveness in an In Vivo/In Vitro Model for Myometrial Tumorigenesis

C. Walker, J. Everitt, M. Gottardis, 1995, Annals of the New York Academy of Sciences.

Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen.

S. Robinson, V. Jordan, M. Gottardis, 1988, Journal of steroid biochemistry.

Biochemical and transcriptional profiling to triage additional activities in a series of IGF-1R/IR inhibitors.

P. Ross-Macdonald, H. de Silva, Isaac Neuhaus, 2012, Bioorganic & Medicinal Chemistry.

Decreased Egr‐1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation

D. Mercola, E. Adamson, M. Gottardis, 1997, International journal of cancer.

ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.

P. Sorensen, N. Melnyk, C. Tognon, 2011, Cancer research.

Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.

D. Leroith, A. Rowzee, T. Wood, 2010, Cancer research.

Molecular insights into breast cancer from transgenic mouse models

G. Merlino, R. Dickson, M. Gottardis, 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.

S. P. Seitz, M. Gottardis, R. Attar, 2010, Bioorganic & medicinal chemistry letters.

Sensitive and specific detection of retinoid receptor subtype proteins in cultured cell and tumor extracts.

M. Gottardis, J. Pike, E. Allegretto, 1994, Molecular endocrinology.

Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer.

A. Wolff, D. Nuyten, F. Huang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The dual IGF-1 R / InsR inhibitor , BMS-754807 , demonstrates synergy in combination with hormonal agents in vitro and enhances in vivo activity in an estrogen-dependent breast cancer model

F. Huang, P. Haluska, M. Gottardis, 2011 .

Therapeutics , Targets , and Chemical Biology Dual IGF-1 R / InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer

F. Huang, P. Haluska, M. Gottardis, 2011 .

Influence of Extreme Long Endurance Sports Activity on Neopterin Excretion

D. Fuchs, M. Gottardis, K. Schroecksnadel, 2008 .

Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase.

Chiehying Y Chang, M. Gottardis, R. Attar, 2007, Bioorganic & medicinal chemistry letters.

Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines.

T. Goldsworthy, C. Walker, D. Wolf, 1995, The American journal of pathology.

The secretion of human growth hormone stimulated by human growth hormone releasing factor following severe cranio-cerebral trauma

C. Putensen, M. Gottardis, J. Hackl, 2005, Intensive Care Medicine.

Effect of prolonged sedation with propofol on serum triglyceride and cholesterol concentrations.

M. Gottardis, J. Hackl, W. Koller, 1989, British journal of anaesthesia.

Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors.

L. Mueller, S. Sheriff, David K. Williams, 2006, Bioorganic & medicinal chemistry letters.

Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells.

M. Gottardis, R. Jäger, G. Zugmaier, 1996, British Journal of Cancer.

Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.

J. Hunt, M. Salvati, A. Balog, 2005, Bioorganic & medicinal chemistry letters.

Identification of a Novel Transcription Factor, GAGATA-binding Protein, Involved in Androgen-mediated Expression of Prostate-specific Antigen*

L. Chung, C. Kao, Chihuei Wang, 2003, Journal of Biological Chemistry.

Improvement of septic syndrome after administration of recombinant human growth hormone (rhGH)?

A. Benzer, M. Gottardis, J. Hackl, 1991, The Journal of trauma.

Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transport.

J. Fargnoli, R. Talbott, J. Hunt, 2015, Experimental cell research.

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

C. Drake, E. Antonarakis, D. McNeel, 2019, Prostate Cancer and Prostatic Diseases.

Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924

Y. Asmann, F. Huang, K. Flatten, 2011, Molecular Cancer Therapeutics.

The Discovery of BMS-737 as a Potent, CYP17 Lyase-Selective Inhibitor for the Treatment of Castration-Resistant Prostate Cancer.

J. Tokarski, A. Fura, L. Jayaraman, 2022, Bioorganic & medicinal chemistry letters.

Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer.

A. Doweyko, G. Trainor, A. Fura, 2016, ACS medicinal chemistry letters.

5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.

M. Gottardis, T. K. Jones, C. Tegley, 1998, Journal of medicinal chemistry.

Cancer esearch apeutics , Targets , and Chemical Biology erential Mechanisms of Acquired Resistance to Insulin-Growth Factor-I Receptor Antibody Therapy or to a all-Molecule Inhibitor , BMS-754807 , in a Human R bdomyosarcoma Model

Han Chang, M. Gottardis, A. Greer, 2010 .

Blocking IGF1R signaling in ETV6-NTRK3 breast cancer

N. Melnyk, C. Tognon, Valentina Evdokimova, 2010 .

Are Hypotension and Rash After Atracurium Really Caused by Histamine Release?

W. Lorenz, M. Gottardis, A. Doenicke, 1994, Anesthesia and analgesia.

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2

P. Ross-Macdonald, K. McIntyre, G. Trainor, 2012, Leukemia.

Laminin adhesion-selected primary human colon-cancer cells are more tumorigenic than the parenteral and nonadherent cells.

H. Kleinman, M. Gottardis, M. Kibbey, 1994, International journal of oncology.

Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.

D. Langley, M. Gottardis, R. Attar, 2008, Bioorganic & medicinal chemistry letters.

Constitutively Active Insulin-Like Growth Factor I Receptor Tumor Development by Transgenic Expression of a

Adrian V. Lee, F. Lee, D. Bol, 2005 .

Separation of Retinoid X Receptor Homo- and Heterodimerization Functions

H. Gronemeyer, M. Gottardis, W. Bourguet, 2003, Molecular and Cellular Biology.

Identification of novel functional inhibitors of 17β‐hydroxysteroid dehydrogenase type III (17β‐HSD3)

I. Takenaka, B. Fink, M. Salvati, 2005 .

Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer

Yolanda T. Chong, T. Bush, G. Bignan, 2021, Molecular Cancer Therapeutics.

Title: Discovery of JNJ-63576253, a next-generation androgen receptor antagonist active against wild- type and clinically-relevant ligand binding domain mutations in metastatic castration-resistant prostate cancer (mCRPC) Running Title: Discovery of JNJ-63576253, a next-generation AR antagonist

Yolanda T. Chong, T. Bush, G. Bignan, 2021 .

Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer.

L. Schweizer, M. Salvati, Weifang Shan, 2009, Cancer research.

The androgen receptor can signal through Wnt/β-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens

L. Schweizer, M. Gottardis, R. Attar, 2008, BMC Cell Biology.

Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activ

Zheng Yang, Sean Kim, Praveen Balimane, 2008, Journal of medicinal chemistry.

Preparation, resolution, and biological evaluation of 5-aryl-1, 2-dihydro-5H-chromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists.

J. Edwards, M. Gottardis, C. Pathirana, 1998, Journal of medicinal chemistry.

5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.

M. Gottardis, E. Kallel, T. K. Jones, 1998, Journal of medicinal chemistry.

5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.

J. Edwards, M. Gottardis, T. K. Jones, 1998, Bioorganic & medicinal chemistry letters.

In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

C. Conover, F. Lee, D. Loegering, 2006, Cancer research.

Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.

M. Gottardis, R. Heyman, W. Lamph, 1996, Cancer research.

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

Zheng Yang, G. Trainor, F. Lee, 2009, Molecular Cancer Therapeutics.

BMS-536924 Reverses IGF-IR-Induced Transformation of Mammary Epithelial Cells and Causes Growth Inhibition and Polarization of MCF7 Cells

Adrian V. Lee, B. Litzenburger, C. Fairchild, 2009, Clinical Cancer Research.

5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents.

J. Edwards, M. Gottardis, T. K. Jones, 1998, Journal of Medicinal Chemistry.

5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.

M. Gottardis, T. K. Jones, C. Tegley, 1998, Journal of medicinal chemistry.

The efficacy of 9-cis retinoic acid in experimental models of cancer

A. Wellstein, M. Gottardis, D. Shalinsky, 2005, Breast Cancer Research and Treatment.

High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling

A. Trumpp, J. Aster, A. Weng, 2011, The Journal of experimental medicine.

Additive effects of c‐erbB‐2, c‐Ha‐ras, and transforming growth factor‐α genes on in vitro transformation of human mammary epithelial cells

N. Normanno, D. Salomon, F. Ciardiello, 1992, Molecular carcinogenesis.

Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tetrahydroisoquinoline lead series.

Wayne Vaccaro, Steven Sheriff, Neil Burford, 2006, Bioorganic & medicinal chemistry letters.

Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).

I. Takenaka, B. Fink, M. Salvati, 2005, The Prostate.

Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes

C. Takimoto, M. Gottardis, R. Attar, 2009, Clinical Cancer Research.

BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.

A. Yasmeen, M. Pollak, M. Gottardis, 2009, Gynecologic oncology.

The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.

Xia Han, F. Huang, F. Lee, 2009, Cancer research.

Rationale for Combining with EGFR / HER 2 Inhibitors Growth Factor-1 Receptor Inhibitor ( BMS-536924 ) and The Mechanisms of Differential Sensitivity to an Insulin-like Updated

Xia Han, F. Huang, F. Lee, 2008 .

Constitutively Active Type I Insulin-Like Growth Factor Receptor Causes Transformation and Xenograft Growth of Immortalized Mammary Epithelial Cells and Is Accompanied by an Epithelial-to-Mesenchymal Transition Mediated by NF-κB and Snail

Adrian V. Lee, B. Litzenburger, X. Cui, 2007, Molecular and Cellular Biology.

Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers.

M. Modugno, D. Ballinari, W. Pastori, 2015, Experimental cell research.

Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).

Yolanda T. Chong, T. Bush, G. Bignan, 2021, Journal of medicinal chemistry.

- Nitrosomethylurea-induced Rat Mammary Carcinoma Model N Antitumor Actions of Keoxifene and Tamoxifen in the Updated Version

V. Jordan, M. Gottardis, 2006 .

Expression of transforming growth factor α antisense mRNA inhibits the estrogen‐induced production of TGFα and estrogen‐induced proliferation of estrogen‐responsive human breast cancer cells

N. Normanno, D. Salomon, F. Ciardiello, 1993 .

Quality indicators increase the reliability of microarray data.

Doulaye Dembélé, Wolfgang Raffelsberger, Hinrich Gronemeyer, 2002, Genomics.

Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer

M. Morris, H. Scher, G. Wilding, 2010, Clinical Cancer Research.

Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.

Derek J. Norris, J. Tokarski, S. D. Kimball, 2006, Bioorganic & medicinal chemistry letters.

Effect of haemodilution on transfusion requirements in liver resection

A. Benzer, M. Gottardis, F. Pühringer, 1990, The Lancet.

Airless Identification of the Epidural Space in Infants and Children

M. Gottardis, R. Germann, W. Furtwangler, 2006 .

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924

C. Erlichman, P. Haluska, M. Gottardis, 2008, Molecular Cancer Therapeutics.

[The automated determination of the dibucaine number using the Greiner G450 selective analyzer. A routine parameter of significance?].

A. Benzer, W. Schobersberger, M. Gottardis, 1990, Der Anaesthesist.

High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy

Adrian V. Lee, S. Hilsenbeck, B. Litzenburger, 2010, Clinical Cancer Research.

Spirometry, blood gas analysis and ultrasonography of the diaphragm after Winnie's interscalene brachial plexus block.

A. Benzer, M. Gottardis, H. Resch, 1993, European journal of anaesthesiology.

Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.

M. Gottardis, R. Heyman, W. Lamph, 1998, Cancer research.

General anaesthesia in a patient with motor neuron disease.

M. Gottardis, P. Lirk, B. Moser, 2004, European journal of anaesthesiology.

Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors.

Charles Y. Lin, S. Knapp, T. Westbrook, 2020, Cell chemical biology.

IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein.

A. Weng, Christopher R Jenkins, V. Giambra, 2012, Experimental hematology.

Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.

R. Lloyd, P. Haluska, M. Ames, 2010, Endocrine-related cancer.

Post-transcriptional destabilization of estrogen receptor mRNA in MCF-7 cells by 12-O-tetradecanoylphorbol-13-acetate.

R. Dickson, M. Lippman, M. Gottardis, 1991, The Journal of biological chemistry.

Sensitivity and insensitivity of breast cancer to tamoxifen

V. Jordan, M. Gottardis, D. Gibson, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.

D. Loegering, B. Smith, J. Karp, 2009, Cancer research.

Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro.

E. Borden, V. Jordan, M. Gottardis, 1989, Cancer research.

Rat mammary carcinoma regressions during suppression of serum growth hormone and prolactin.

M. Gottardis, D. Rose, J. Noonan, 1983, Anticancer Research.

Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma.

S. Avnet, M. Salerno, N. Baldini, 2009, Cancer research.

A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor

Martin C. Wright, A. Yamniuk, M. Doyle, 2011, mAbs.

Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3.

Jonathan Lippy, John S Tokarski, David S Nirschl, 2011, Bioorganic & medicinal chemistry letters.

Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma.

J. Copland, R. Broaddus, S. Fischer, 2003, Cancer research.

9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice.

S. Hilsenbeck, P. Brown, J. Green, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma.

R. Fuchs-Young, C. Walker, K. Burroughs, 2000, The Journal of pharmacology and experimental therapeutics.

Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.

Adrian V. Lee, F. Lee, D. Bol, 2005, Cancer research.

Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors

G. Wilding, R. Martell, M. Gottardis, 2007, Clinical Cancer Research.

Strategies for breast cancer therapy with antiestrogens.

V. Jordan, M. Gottardis, V C Jordan, 1987, Journal of steroid biochemistry.

Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor.

T. Willson, M. Dewhirst, G. Broadwater, 2001, Cancer research.

Efficacy of LGD 1069 ( Targretin ) , a Retinoid X Receptor-Selective Ligand , for Treatment of Uterine Leiomyoma 1

R. Fuchs-Young, C. Walker, K. Burroughs, 2000 .

Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.

J. Fargnoli, F. Huang, M. Gottardis, 2010, Cancer research.

Rodent model of reproductive tract leiomyomata: characterization and use in preclinical therapeutic studies.

C. Walker, M. Gottardis, J. Everitt, 1997, Progress in clinical and biological research.

Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.

K. Kish, S. Krystek, M. Salvati, 2005, Bioorganic & medicinal chemistry letters.

Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival Pathways

C. Logothetis, M. Gottardis, G. Gallick, 2012, PloS one.

Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.

P. Sorensen, S. Aparicio, S. McKinney, 2010, Cancer research.

Insulin Receptor A and IGF-IR in AML – Response

J. Karp, C. Erlichman, S. Kaufmann, 2010 .

An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer.

N. Agarwal, J. Infante, D. Rathkopf, 2019, Journal of Clinical Oncology.

Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807.

F. Huang, M. Gottardis, R. Attar, 2010, Endocrinology.

IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.

M. Pollak, M. Gottardis, E. Birman, 2011, Endocrine-related cancer.

Evaluation of thyroid hormones as predictor of outcome in patients after major trauma.

A. Benzer, M. Gottardis, T. Luger, 1993, Thyroid.

Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

C. Drake, P. Sharma, P. Troncoso, 2023, Journal for ImmunoTherapy of Cancer.

Regulation of retinoblastoma gene expression in hormone-dependent breast cancer.

M. Lippman, M. Gottardis, Y. Fung, 1995, Endocrinology.

Effect of progesterone administration on rat endometrial disease after exposure to N-nitrosomethylurea.

M. Gottardis, D. Rose, E. Ertürk, 1982, European journal of cancer & clinical oncology.

Growth Factor-a Genes on In Vitro Transformation of Human Mammary Epithelial Cells

N. Normanno, F. Ciardiello, F. Basolo, 2006 .

Expression of transforming growth factor alpha antisense mRNA inhibits the estrogen-induced production of TGF alpha and estrogen-induced proliferation of estrogen-responsive human breast cancer cells.

N. Normanno, F. Ciardiello, M. Cutler, 1993, Journal of cellular physiology.

IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors

S. Weroha, P. Haluska, M. Gottardis, 2012, Clinical Cancer Research.

The androgen receptor can signal through Wnt/β-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens

L. Schweizer, M. Gottardis, R. Attar, 2008, BMC Cell Biology.

Complete IGF Signaling Blockade by the Dual-Kinase Inhibitor, BMS-754807, Is Sufficient To Overcome Tamoxifen and Letrozole Resistance In Vitro and In Vivo.

F. Huang, P. Haluska, M. Gottardis, 2009 .

Drug efflux by breast cancer resistance protein (BCRP) is a mechanism of resistance to the insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.

Y. Asmann, C. T. Eyck, C. Erlichman, 2009 .

The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer

Kaitlyn M. Gayvert, M. Rubin, O. Elemento, 2023, Cancer research communications.

Decreased progesterone binding and attenuated progesterone action in cultured human breast carcinoma cells treated with epidermal growth factor.

W. Blattner, J. Nadeau, C. Pui, 1988, Cancer research.

Cancer esearch apeutics , Targets , and Chemical Biology thetic Lethality Screens Reveal RPS 6 and MST 1 R as ifiers of Insulin-like Growth Factor-1 Receptor R bitor Activity in Childhood Sarcomas

Joan, P. Sorensen, S. Aparicio, 2010 .

thetic Lethality Screens Reveal RPS6 and MST1R as ifiers of Insulin-like Growth Factor-1 Receptor

Joan, P. Sorensen, S. Aparicio, 2010 .

High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy

Adrian V. Lee, S. Hilsenbeck, B. Litzenburger, 2010, Clinical Cancer Research.

Bms-536924 Reverses Igf-ir-induced Transformation of Mammary Epithelial Cells and Causes Growth Inhibition and Polarization of Mcf7 Cells Cancer Therapy: Preclinical

B. Litzenburger, M. Gottardis, I. Kuiatse, 2022 .

High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines Correlates with Sensitivity to IGF-IR Inhibitor BMS-754807 in This Subtype of Human Breast Cancer.

Jeffrey T. Chang, Adrian V. Lee, B. Litzenburger, 2009 .